Presented by Incubate, America's medicine cabinet is running out. Researchers are advancing

cures for cancer, Alzheimer's, and more, but the pill penalty is putting progress on pause.

It slaps price controls on pills years earlier than other medicines, stalling investment and denying

hope to millions. Through budget reconciliation, Congress can

fix it. It's time to act and end the pill penalty.

Hey everybody, it's Anna Palmer from The Daily Punch.

Welcome to the first special edition podcast for our Future of Medicine series.

This month, we're laying out the state of play, engaging in key interviews with leaders in the space and the outlook on what's to come.

A big thank you to incubate for making this podcast and product possible.

You can check out the full project at punchable.

Today, I'm going to be speaking with Alvina Navaguna, our special project editor at Punchbowl News.

We're going to be discussing the future of medicine.

Elvina writes, in the two decades since technological advances,

investment from the venture capitalist world,

and changing regulatory environments have sparked significant changes in the life sciences industry.

In this segment, we'll explore the interplay of regulations,

innovation, the drive for profit,

and how technological advancements are shaping the future of medicine. Alvina, thank you so much for joining me. Thank you,

Anna. All right, set us up here. Let's talk about the state of play. Where do things stand at that

100,000 foot level?

So the big thing when we're thinking about the future of medicine is the process of taking a drug from the beginning to a patient's bedside.

And that's the big issue that the industry is grappling with.

...